First Author: G.Seymenoglu TURKEY
Co Author(s): C. Cansız E. Başer 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate the outcomes of patients with vitreomacular traction syndrome (VMT) treated with triamcinolone acetonid (TA) assisted 23-gauge (23-G) transconjunctival sutureless vitrectomy.
Celal Bayar University Hospital Department of Ophthalmology
Restrospective, case series. The medical charts of 13 eyes of 13 consecutive patients with VMT who underwent 23-gauge transconjunctival pars plana vitrectomy were reviewed. All patients had at least six-month follow-up. The main outcome parameters were changes in best corrected visual acuity (BCVA) and central macular thickness (CMT) between the baseline and postoperative follow- up examinations performed at the first and sixth months after the surgery.
The mean follow-up period was 8 (range 6-15) months. The mean preoperative BCVA was 0.77±0.29 (logmar). The BCVA was 0.68±0.28 (logmar) (p = 0.026) at postoperative 1 month, and 0.63±0.23 (logmar) (p = 0.026) at final visit. The mean CMT was 537±22 µm at baseline, which was significantly reduced to 257±12 µm (p=0.005)at 1 month and 223±11 µm at the final follow-up visit (p = 0.005). No postoperative complications were seen such as endophthalmitis, retinal detachment, hypotony, or glaucoma.
Triamcinolone assisted 23-G transconjunctival sutureless vitrectomy is an effective and safe surgical technique in the management of VMT syndrome. Further studies with large case series are needed.